Anxhela Hasanlli, MD; John H. Rundback, MD, FAHA, FSVM, FSIR; Kevin Herman, MD; Edel Mendoza, MD
The authors present a retrospective case series of 3 patients with ALI who underwent DVA due to persistent, unresolvable limb-threatening tibiopedal occlusive disease after failed endovascular or surgical procedures.
The authors present a retrospective case series of 3 patients with ALI who underwent DVA due to persistent, unresolvable limb-threatening tibiopedal occlusive disease after failed endovascular or surgical procedures.
This review examines CLTI as a systems disease, focusing on failure points in recognition, referral, and access; why delays translate into limb loss and death; organizational models that mitigate delay; and more.
This review examines CLTI as a systems disease, focusing on failure points in recognition, referral, and access; why delays translate into limb loss and death; organizational models that mitigate delay; and more.
Dr Elizabeth Genovese challenged the reflexive “endo-first” mindset in CLTI and asked a more nuanced question: when should bypass be considered first—and why?
Dr Elizabeth Genovese challenged the reflexive “endo-first” mindset in CLTI and asked a more nuanced question: when should bypass be considered first—and why?
Andrew Holden, MBChB, FRANZCR, delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
Andrew Holden, MBChB, FRANZCR, delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
At AMP 2025, Interventional radiologist Jos van den Berg, MD, PhD, from the Clinica Luganese Moncucco in Lugano, Switzerland, delivered a presentation titled “The Economic Burden of CLTI in Europe.”
At AMP 2025, Interventional radiologist Jos van den Berg, MD, PhD, from the Clinica Luganese Moncucco in Lugano, Switzerland, delivered a presentation titled “The Economic Burden of CLTI in Europe.”
Richard Neville, MD, outlines how CLTI programs are redefining “quality.” The era of anecdotal morbidity and mortality reviews has given way to continuous, data-driven evaluation aligned with value-based care.
Richard Neville, MD, outlines how CLTI programs are redefining “quality.” The era of anecdotal morbidity and mortality reviews has given way to continuous, data-driven evaluation aligned with value-based care.
